1. Neurath, M.F., New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol, 2014. 7(1): p. 6-19.
2. Loftus, E.V., Jr., Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 2004. 126(6): p. 1504-17.
3. Mohamadzadeh, M., et al., Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A, 2011. 108 Suppl 1(Suppl 1): p. 4623-30.
4. Neurath, M.F., Cytokines in inflammatory bowel disease. Nat Rev Immunol, 2014. 14(5): p. 329-42.
5. Maloy, K.J. and F. Powrie, Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature, 2011. 474(7351): p. 298-306.
6. Francescone, R., V. Hou, and S.I. Grivennikov, Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis, 2015. 21(2): p. 409-18.
7. Bramuzzo, M., et al., Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterol J, 2019. 7(6): p. 759-766.
8. Papamichael, K., et al., Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis, 2019. 13(8): p. 976-981.
9. Ferrante, M., et al., Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis, 2008. 2(3): p. 219-25.
10. Ke, F., P.K. Yadav, and L.Z. Ju, Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol, 2012. 18(1): p. 3-10.
11. Ge, F., et al., Anti-inflammatory effects of Fagopyrum cymosum administered as a potential drug for ulcerative colitis. Exp Ther Med, 2017. 14(5): p. 4745-4754.
12. Wang, K., et al., Bergenin, Acting as an Agonist of PPARγ, Ameliorates Experimental Colitis in Mice through Improving Expression of SIRT1, and Therefore Inhibiting NF-κB-Mediated Macrophage Activation. Front Pharmacol, 2017. 8: p. 981.
13. Yamada, S., et al., Marine hydroquinone zonarol prevents inflammation and apoptosis in dextran sulfate sodium-induced mice ulcerative colitis. PLoS One, 2014. 9(11): p. e113509.
14. Zhu, G., et al., Ginsenoside Rg1 attenuates the inflammatory response in DSS-induced mice colitis. Int Immunopharmacol, 2017. 50: p. 1-5.
15. Chen, F., L. Li, and D.D. Tian, Salvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug Interactions. Biomed Res Int, 2017. 2017: p. 9868694.
16. Zhu, W., et al., Sodium tanshinone II A sulfonate ameliorates microcirculatory disturbance of small intestine by attenuating the production of reactie oxygen species in rats with sepsis. Chin J Integr Med, 2016. 22(10): p. 745-51.
17. Wang, K., et al., Protective Effects of Salvianolic Acid A against Dextran Sodium Sulfate-Induced Acute Colitis in Rats. Nutrients, 2018. 10(6).
18. Xiong, Y., et al., Salvianolic Acid B Restored Impaired Barrier Function via Downregulation of MLCK by microRNA-1 in Rat Colitis Model. Front Pharmacol, 2016. 7: p. 134.
19. Fan, H.Y., et al., Antiplatelet and antithrombotic activities of salvianolic acid A. Thromb Res, 2010. 126(1): p. e17-22.
20. Novacek, G., et al., Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology, 2010. 139(3): p. 779-87, 787.e1.
21. Nguyen, G.C., et al., Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology, 2014. 146(3): p. 835-848.e6.
22. Chande, N., Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease. Inflamm Bowel Dis, 2013. 19(3): p. 669-71.
23. Chande, N., et al., Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis, 2011. 17(9): p. 1979-86.
24. Stadnicki, A., Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol, 2012. 10(5): p. 659-69.
25. Senchenkova, E., H. Seifert, and D.N. Granger, Hypercoagulability and Platelet Abnormalities in Inflammatory Bowel Disease. Semin Thromb Hemost, 2015. 41(6): p. 582-9.
26. Di Sabatino, A., et al., Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment. Thromb Haemost, 2016. 116(3): p. 486-95.
27. Järemo, P. and H. Sandberg-Gertzen, Platelet density and size in inflammatory bowel disease. Thromb Haemost, 1996. 75(4): p. 560-1.
28. Mascaraque, C., et al., Intestinal anti-inflammatory activity of apigenin K in two rat colitis models induced by trinitrobenzenesulfonic acid and dextran sulphate sodium. Br J Nutr, 2015. 113(4): p. 618-26.
29. Feldman, A.T. and D. Wolfe, Tissue processing and hematoxylin and eosin staining. Methods Mol Biol, 2014. 1180: p. 31-43.
30. Eichele, D.D. and K.K. Kharbanda, Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol, 2017. 23(33): p. 6016-6029.
31. Perše, M. and A. Cerar, Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol, 2012. 2012: p. 718617.
32. Massafra, V., et al., Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim Biophys Acta, 2016. 1862(2): p. 166-73.
33. Stephens, M. and P.Y. von der Weid, Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner. Gut Microbes, 2020. 11(3): p. 421-432.
34. Catana, C.S., et al., Comparison of two models of inflammatory bowel disease in rats. Adv Clin Exp Med, 2018. 27(5): p. 599-607.
35. Kiesler, P., I.J. Fuss, and W. Strober, Experimental Models of Inflammatory Bowel Diseases. Cell Mol Gastroenterol Hepatol, 2015. 1(2): p. 154-170.
36. Cosnes, J., et al., Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology, 2011. 140(6): p. 1785-94.
37. Keller, D.S., et al., Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol, 2019. 23(1): p. 3-13.
38. Pandey, A., C. Shen, and S.M. Man, Inflammasomes in Colitis and Colorectal Cancer: Mechanism of Action and Therapies. Yale J Biol Med, 2019. 92(3): p. 481-498.
39. Cao, S.G., et al., Cryptotanshinone inhibits prostaglandin E2 production and COX-2 expression via suppression of TLR4/NF-κB signaling pathway in LPS-stimulated Caco-2 cells. Microb Pathog, 2018. 116: p. 313-317.
40. Jin, B.R., et al., Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. Sci Rep, 2017. 7: p. 46252.
41. Tian, Y., et al., Fecal microbiota transplantation for ulcerative colitis: a prospective clinical study. BMC Gastroenterol, 2019. 19(1): p. 116.
42. Seishima, J., et al., Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol, 2019. 20(1): p. 252.
43. Coqueiro, A.Y., et al., Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. Int J Food Sci Nutr, 2019. 70(1): p. 20-29.
44. Cai, H., et al., Danshen can interact with intestinal bacteria from normal and chronic renal failure rats. Biomed Pharmacother, 2019. 109: p. 1758-1771.
45. Wang, L., et al., Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. Biomed Pharmacother, 2020. 128: p. 110262.
46. Wen, X.D., et al., Salvia miltiorrhiza (dan shen) significantly ameliorates colon inflammation in dextran sulfate sodium induced colitis. Am J Chin Med, 2013. 41(5): p. 1097-108.
47. Zhang, X., et al., Tanshinone IIA ameliorates dextran sulfate sodium-induced inflammatory bowel disease via the pregnane X receptor. Drug Des Devel Ther, 2015. 9: p. 6343-62.
48. Min, X., et al., Cryptotanshinone protects dextran sulfate sodium-induced experimental ulcerative colitis in mice by inhibiting intestinal inflammation. Phytother Res, 2020.